{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:16:17Z","timestamp":1788441377199,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01588-7","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:36:25Z","timestamp":1788438985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of Claudin 18.2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4949-9417","authenticated-orcid":false,"given":"Fazal Elahi","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendranandini","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan","family":"Dodeja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel Amorim Moreira","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Harby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rida","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahbaz","family":"Madappattuparambil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"issue":"3","key":"1588_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"10251","key":"1588_CR2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, Van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(20)31288-5.","journal-title":"Lancet"},{"issue":"9742","key":"1588_CR3","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X.","journal-title":"Lancet"},{"issue":"10294","key":"1588_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2.","journal-title":"Lancet"},{"issue":"11","key":"1588_CR5","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P, Bai Y, Ryu MH, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(23)00515-6.","journal-title":"Lancet Oncol"},{"issue":"21","key":"1588_CR6","doi-asserted-by":"publisher","first-page":"7380","DOI":"10.1128\/MCB.21.21.7380-7390.2001","volume":"21","author":"T Niimi","year":"2001","unstructured":"Niimi T, Nagashima K, Ward JM, Minoo P, Zimonjic DB, Popescu NC, et al. claudin-18, a Novel Downstream Target Gene for the T\/EBP\/NKX2.1 Homeodomain Transcription Factor, Encodes Lung- and Stomach-Specific Isoforms through Alternative Splicing. Mol Cell Biol. 2001;21(21):7380\u201390. https:\/\/doi.org\/10.1128\/MCB.21.21.7380-7390.2001.","journal-title":"Mol Cell Biol"},{"issue":"23","key":"1588_CR7","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G, et al. Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development. Clin Cancer Res. 2008;14(23):7624\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1547.","journal-title":"Clin Cancer Res"},{"issue":"10389","key":"1588_CR8","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(23)00620-7.","journal-title":"Lancet"},{"issue":"8","key":"1588_CR9","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133\u201341. https:\/\/doi.org\/10.1038\/s41591-023-02465-7.","journal-title":"Nat Med"},{"issue":"1","key":"1588_CR10","doi-asserted-by":"publisher","first-page":"100762","DOI":"10.1016\/j.esmoop.2022.100762","volume":"8","author":"Y Kubota","year":"2023","unstructured":"Kubota Y, Kawazoe A, Mishima S, Nakamura Y, Kotani D, Kuboki Y, et al. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open. 2023;8(1):100762. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100762.","journal-title":"ESMO Open"},{"issue":"11","key":"1588_CR11","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3390\/jpm11111095","volume":"11","author":"A Pellino","year":"2021","unstructured":"Pellino A, Brignola S, Riello E, Niero M, Murgioni S, Guido M, et al. Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas. J Pers Med. 2021;11(11):1095. https:\/\/doi.org\/10.3390\/jpm11111095.","journal-title":"J Pers Med"},{"key":"1588_CR12","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;n71. https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"issue":"4","key":"1588_CR13","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.21037\/jgo-2025-111","volume":"16","author":"S Wallam","year":"2025","unstructured":"Wallam S, Park J, Wu LW, Moy RH. Retrospective analysis of Claudin18.2 expression in ethnically diverse patients with gastroesophageal adenocarcinoma. J Gastrointest Oncol. 2025;16(4):1420\u201333. https:\/\/doi.org\/10.21037\/jgo-2025-111.","journal-title":"J Gastrointest Oncol"},{"issue":"3","key":"1588_CR14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.pathol.2025.10.015","volume":"58","author":"HH Chen","year":"2026","unstructured":"Chen HH, Liau JY, Jeng YM, Chen KH, Tsai JH. Claudin-18.2 expression is frequent in remnant gastric carcinoma and associated with microsatellite instability and Epstein\u2013Barr viral infection phenotypes. Pathol (Phila). 2026;58(3):276\u201383. https:\/\/doi.org\/10.1016\/j.pathol.2025.10.015.","journal-title":"Pathol (Phila)"},{"issue":"3","key":"1588_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","volume":"13","author":"Z Munn","year":"2015","unstructured":"Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthc. 2015;13(3):147\u201353. https:\/\/doi.org\/10.1097\/XEB.0000000000000054.","journal-title":"Int J Evid Based Healthc"},{"issue":"5","key":"1588_CR16","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1007\/s10120-024-01518-1","volume":"27","author":"K Shitara","year":"2024","unstructured":"Shitara K, Xu RH, Ajani JA, Moran D, Guerrero A, Li R, et al. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Gastric Cancer. 2024;27(5):1058\u201368. https:\/\/doi.org\/10.1007\/s10120-024-01518-1.","journal-title":"Gastric Cancer"},{"issue":"11","key":"1588_CR17","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.3760\/cma.j.cn112151-20250508-00331","volume":"54","author":"CS Wang","year":"2025","unstructured":"Wang CS, Zhang D, Zhang X, Liu FC, Shi QY, Wu HY, Xia HP, Sun Q, Li L. [Consistency of claudin 18.2 expression with antibodies of different clones in gastric adenocarcinoma]. Zhonghua Bing Li Cue Za Zhi. 2025 Nov 8;54(11):11144\u20131149. https:\/\/doi.org\/10.3760\/cma.j.cn112151-20250508-00331","journal-title":"Chin J"},{"issue":"6","key":"1588_CR18","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s00428-025-04247-7","volume":"487","author":"C Martinez-Ciarpaglini","year":"2025","unstructured":"Martinez-Ciarpaglini C, Ortega M, P\u00e9rez-Buira S, Bolea A, Casado Guerra B, Herencia Bellido C, et al. CLDN18.2 expression in gastroesophageal adenocarcinoma: prevalence, heterogeneity, and prognostic implications in Spanish patients. Virchows Arch. 2025;487(6):1337\u201346. https:\/\/doi.org\/10.1007\/s00428-025-04247-7.","journal-title":"Virchows Arch"},{"issue":"1","key":"1588_CR19","doi-asserted-by":"publisher","first-page":"28958","DOI":"10.1038\/s41598-025-12337-4","volume":"15","author":"S Pak","year":"2025","unstructured":"Pak S, Simon AG, Lyu SI, Tolkach Y, Alakus H, Zander T, et al. The expression of the tight junction protein and therapeutical target Claudin 18.2 is heterogeneously distributed within esophageal and gastric adenocarcinoma. Sci Rep. 2025;15(1):28958. https:\/\/doi.org\/10.1038\/s41598-025-12337-4.","journal-title":"Sci Rep"},{"issue":"12","key":"1588_CR20","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1097\/PAS.0000000000002464","volume":"49","author":"BL Liu","year":"2025","unstructured":"Liu BL, Cleary JM, Shi J, Hornick JL, Zhao L. Claudin 18.2 and Other Therapeutic Biomarkers in Gastric and Gastroesophageal Junction Adenocarcinomas. Am J Surg Pathol. 2025;49(12):1233\u201344. https:\/\/doi.org\/10.1097\/PAS.0000000000002464.","journal-title":"Am J Surg Pathol"},{"key":"1588_CR21","doi-asserted-by":"publisher","unstructured":"Waters R, Sewastjanow-Silva M, Yamashita K, Abdelhakeem A, Iwata KK, Moran D, et al. Retrospective Study of Claudin 18 Isoform 2 Prevalence and Prognostic Association in Gastric and Gastroesophageal Junction Adenocarcinoma. JCO Precis Oncol. 2024;8e2300543. https:\/\/doi.org\/10.1200\/PO.23.00543.","DOI":"10.1200\/PO.23.00543"},{"issue":"2","key":"1588_CR22","doi-asserted-by":"publisher","first-page":"oyae238","DOI":"10.1093\/oncolo\/oyae238","volume":"30","author":"Y Kwak","year":"2025","unstructured":"Kwak Y, Kim TY, Nam SK, Hwang HJ, Han D, Oh HJ, et al. Clinicopathologic and molecular characterization of stages II-IV gastric cancer with Claudin 18.2 expression. Oncologist. 2025;30(2):oyae238. https:\/\/doi.org\/10.1093\/oncolo\/oyae238.","journal-title":"Oncologist"},{"issue":"4","key":"1588_CR23","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1007\/s10120-024-01505-6","volume":"27","author":"H Ogawa","year":"2024","unstructured":"Ogawa H, Abe H, Yagi K, Seto Y, Ushiku T. Claudin-18 status and its correlation with HER2 and PD-L1 expression in gastric cancer with peritoneal dissemination. Gastric Cancer. 2024;27(4):802\u201310. https:\/\/doi.org\/10.1007\/s10120-024-01505-6.","journal-title":"Gastric Cancer"},{"issue":"12","key":"1588_CR24","doi-asserted-by":"publisher","first-page":"104000","DOI":"10.1016\/j.esmoop.2024.104000","volume":"9","author":"TY Kim","year":"2024","unstructured":"Kim TY, Kwak Y, Nam SK, Han D, Oh DY, Im SA, et al. Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancer. ESMO Open. 2024;9(12):104000. https:\/\/doi.org\/10.1016\/j.esmoop.2024.104000.","journal-title":"ESMO Open"},{"issue":"1","key":"1588_CR25","doi-asserted-by":"publisher","first-page":"17648","DOI":"10.1038\/s41598-024-68411-w","volume":"14","author":"E Choi","year":"2024","unstructured":"Choi E, Shin J, Ryu MH, Kim HD, Park YS. Heterogeneity of claudin 18.2 expression in metastatic gastric cancer. Sci Rep. 2024;14(1):17648. https:\/\/doi.org\/10.1038\/s41598-024-68411-w.","journal-title":"Sci Rep"},{"issue":"2","key":"1588_CR26","doi-asserted-by":"publisher","first-page":"303","DOI":"10.5230\/jgc.2025.25.e2","volume":"25","author":"SM Son","year":"2025","unstructured":"Son SM, Woo CG, Lee OJ, Lee SK, Cho M, Lee YP, et al. Discordance in Claudin 18.2 Expression Between Primary and Metastatic Lesions in Patients With Gastric Cancer. J Gastric Cancer. 2025;25(2):303. https:\/\/doi.org\/10.5230\/jgc.2025.25.e2.","journal-title":"J Gastric Cancer"},{"key":"1588_CR27","doi-asserted-by":"publisher","first-page":"155628","DOI":"10.1016\/j.prp.2024.155628","volume":"263","author":"M Kim","year":"2024","unstructured":"Kim M, Kang BW, Park J, Baek JH, Kim JG. Expression of claudin 18.2 in poorly cohesive carcinoma and its association with clinicopathologic parameters in East Asian patients. Pathol - Res Pract. 2024;263:155628. https:\/\/doi.org\/10.1016\/j.prp.2024.155628.","journal-title":"Pathol - Res Pract"},{"issue":"1","key":"1588_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.21037\/jgo-24-743","volume":"16","author":"A Saito","year":"2025","unstructured":"Saito A, Ohzawa H, Kawashima R, Matsumoto S, Kurashina K, Saito S, et al. Expression of Claudin18.2 in metastatic lesions in peritoneum of gastric cancer. J Gastrointest Oncol. 2025;16(1):67\u201376. https:\/\/doi.org\/10.21037\/jgo-24-743.","journal-title":"J Gastrointest Oncol"},{"issue":"4","key":"1588_CR29","doi-asserted-by":"publisher","first-page":"639","DOI":"10.5230\/jgc.2025.25.e47","volume":"25","author":"S Ahn","year":"2025","unstructured":"Ahn S, Hwang I, Kim KM. Correlation and Overlap Between Claudin 18.2 and FGFR2b Overexpression: A Tissue Microarray Study With 1,538 Gastric Carcinomas. J Gastric Cancer. 2025;25(4):639. https:\/\/doi.org\/10.5230\/jgc.2025.25.e47.","journal-title":"J Gastric Cancer"},{"key":"1588_CR30","doi-asserted-by":"publisher","unstructured":"Zhang Q, Zhao X, Huang X, Hu Y, Wang R, Yin L, et al. Histological and biomarker landscape of Claudin18.2-positive gastric and gastroesophageal junction cancers: a study of 937 cases. Virchows Arch. 2025 Nov;26. https:\/\/doi.org\/10.1007\/s00428-025-04332-x.","DOI":"10.1007\/s00428-025-04332-x"},{"issue":"1","key":"1588_CR31","doi-asserted-by":"publisher","first-page":"20047","DOI":"10.1038\/s41598-023-47178-6","volume":"13","author":"HD Kim","year":"2023","unstructured":"Kim HD, Choi E, Shin J, Lee IS, Ko CS, Ryu MH, et al. Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer. Sci Rep. 2023;13(1):20047. . https:\/\/doi.org\/10.1038\/s41598-023-47178-6","journal-title":"Sci Rep"},{"issue":"4","key":"1588_CR32","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10147-026-02972-w","volume":"31","author":"S Nagano","year":"2026","unstructured":"Nagano S, Kurokawa Y, Hagi T, Motoyama Y, Saito T, Takahashi T, et al. Intratumoral heterogeneity and chemotherapy-induced alteration of CLDN18.2 expression in resectable gastric cancer. Int J Clin Oncol. 2026;31(4):621\u20139. https:\/\/doi.org\/10.1007\/s10147-026-02972-w.","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"1588_CR33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.4132\/jptm.2025.09.11","volume":"60","author":"H Wu","year":"2026","unstructured":"Wu H, Li M, Wang G, Liao P, Zhang P, Yang L, et al. Clinicopathological and molecular mechanisms of CLDN18.2 in gastric cancer aggressiveness: a high-risk population study with multi-omics profiling. J Pathol Transl Med. 2026;60(1):47\u201357. https:\/\/doi.org\/10.4132\/jptm.2025.09.11.","journal-title":"J Pathol Transl Med"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01588-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01588-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01588-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:36:26Z","timestamp":1788438986000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01588-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1588"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01588-7","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"30 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the preparation of this work the authors used generative artificial intelligence to assist with drafting and editing the manuscript text. The authors reviewed and edited all AI-assisted content and take full responsibility for the content of the publication.","order":1,"name":"Ethics","label":"Declaration of Generative AI and AI-assisted Technologies in the Writing Process","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"209"}}